Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD).

Parkinson Study Group Investigators, et al, Paul J Tuite

Research output: Contribution to journal › Article › peer-review

93 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD).'. Together they form a unique fingerprint.

Medicine & Life Sciences